You are here

  • Home
  • Archive
  • Volume 7, Issue 1
  • Follicular lymphoma patients with KIR2DL2 and KIR3DL1 and their ligands (HLA-C1 and HLA-Bw4) show improved outcome when receiving rituximab

Article metrics

Article menu

Download PDFPDF

XML
Research Article
Follicular lymphoma patients with KIR2DL2 and KIR3DL1 and their ligands (HLA-C1 and HLA-Bw4) show improved outcome when receiving rituximab

 

Online download statistics by month:

Online download statistics by month: December 2019 to March 2024

AbstractFullPdf
Dec 2019330
Jan 202016162
Feb 2020990
Mar 202010101
Apr 202010100
May 202013134
Jun 202024242
Jul 2020880
Aug 2020772
Sep 202022227
Oct 2020212011
Nov 202010103
Dec 2020161610
Jan 202118187
Feb 202111116
Mar 202113136
Apr 2021884
May 2021775
Jun 202115156
Jul 202121219
Aug 2021232317
Sep 2021151514
Oct 2021141422
Nov 2021161324
Dec 202116168
Jan 202212134
Feb 2022272710
Mar 2022202113
Apr 2022181911
May 2022303011
Jun 202211119
Jul 202217195
Aug 202222237
Sep 2022192112
Oct 2022886
Nov 202218174
Dec 202213138
Jan 2023996
Feb 202310106
Mar 202327279
Apr 2023998
May 2023121211
Jun 2023992
Jul 2023111115
Aug 202312129
Sep 202311118
Oct 2023994
Nov 2023242510
Dec 2023252510
Jan 202468696
Feb 202418189
Mar 2024151543
Total830835426